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ABSTRACT
Objectives: To assess cost-effectiveness and cost
utility of telerehabilitation (TR) versus standard
rehabilitation (SR) after total knee replacement (TKR).
Design: Markov decision modelling of cost-
effectiveness and cost-utility analysis based on patient-
level and secondary data sources employing Italian
National Health Service (NHS; Ita-NHS) and Society
perspectives.
Setting: Primary care units (PCUs) in Italy.
Participants: Patients discharged after TKR.
Interventions: Mixed SR-TR service (10 face-to-face
sessions and 10 telesessions) versus SR (20 face-to-
face sessions)
Primary and secondary outcome measures: The
incremental cost per additional knee flexion range of
motion (ROM) and per QALY gained by SR-TR
compared with SR. Second, we considered the
probability of being cost-effective and the probability of
being more effective and less expensive.
Results: TR appears to be the cost-effective in the
base case and in all of the considered scenarios, but is
no longer more effective and less expensive if
transportation costs are excluded. Comparing SR-TR
with SR, the incremental cost-effectiveness ratio (ICER)
adopting the Ita-NHS perspective for the base case was
−€117/ROM gained. The cost-effectiveness probability
for SR-TR was 0.98 (ceiling ratio: €50/ROM), while the
joint probability of being more effective and less
expensive was 0.87. Assuming that TR would increase
health-related quality of life (HRQOL) utilities by 2.5%,
the ICER adopting Ita-NHS perspective is −€960/QALY
(cost-effectiveness probability: 1; ceiling ratio: €30 000/
QALY). All the performed sensitivity analyses did not
change the conclusions, but if transportation costs
were excluded, the probability for SR-TR of being more
clinically effective and less expensive reduced to 0.56.
Conclusions: The analysis suggested SR-TR to be
cost-effective, even less expensive and more effective if
the PCUs provide ambulance transportations. However,
the uncertainty related to TR costs, HRQOL and long-
term clinical outcomes raises important topics for
future research, which should be addressed to confirm
our estimates.
Trial registration number: ISRCTN45837371.
INTRODUCTION
Total knee replacement (TKR) is considered
an effective and cost-effective solution to
overcome the most common problems in
osteoarthritis and rheumatic arthritis.1 2 In
11 years, the number of TKRs performed in
Italy has more than doubled (27 959 TKR
performed in 2001; 63 048 TKR in 2012),
and was the 21st most performed procedure
in 2012.3 4 The overall number of procedures
is forecasted to increase further in the next
years due to the reduction in average age of
the population undergoing TKR and the
extension of lifespan.5 Patients are often
treated using standard rehabilitation (SR)
Strengths and limitations of this study
▪ The study assesses cost-effectiveness and cost-
utility for telerehabilitation (TR) after total knee
replacement (TKR) and provides the implications
of the number of transportation for the primary
care units.
▪ The model uses patient-level data for prostheses
survival and health-related quality of life
(HRQOL) utilities from the largest ever con-
ducted pragmatic randomised controlled trial for
TKR.
▪ Effectiveness parameters, HRQOL utilities for TR
and the assumptions in costing standard
rehabilitation-TR are uncertain and need further
investigations.
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after the surgery.6 7 Owing to the number of procedures
undergone each year, TKR and the consequent rehabili-
tation have a high impact in terms of socioeconomic
burden, affecting both costs to the Italian National
Healthcare Service (Ita-NHS) and patients.8According
to Piscitelli and colleagues, productivity losses for
patients who underwent TKR were on average 9 days in
2005. If the time spent in hospital is included, this
increases to 20 days.8 In total, TKR patients aged
younger than 65 years lost 386 586 days of employment
in 2005 or ∼€30 million.9 10 In addition, rehabilitation
cost for the NHS is around €158 million in 2005 (€47
million for hospital rehabilitation and €111 million for
home rehabilitation). However, the current value is
expected to be even higher in the next years due to the
continuing increase in the number of TKRs performed
in Italy.5 Budget allocation for TKR and its related
rehabilitation should be considered as a societal issue
rather than just as an NHS concern. In the past years,
telerehabilitation (TR) has been shown to be non-
inferior to usual care.11–14 Although this evidence was
reinforced in 2015 with a meta-analysis showing a signiﬁ-
cant positive effect of TR after TKR,15 and the presence
of promising results in terms of costs reduction,16 the
actual cost-effectiveness for TR in TKR patients remains
unknown. The aim of the present analysis is to assess the
cost-effectiveness and cost utility of TR versus standard
care after TKR.
METHODS
A Markov model was developed to represent the natural
progression of the TKR and estimate the cost-
effectiveness of a mixed SR-TR programme compared
with SR. The treatments assessed in our economic evalu-
ation were as follows:
1. SR: 20 face-to-face rehabilitation sessions in the fol-
lowing 3 months after TKR.
2. SR-TR: 10 face-to-face rehabilitation sessions and 10
telesessions delivered in the following 3 months after
TKR.
The cost-effectiveness was measured both as incremen-
tal cost per knee ﬂexion range of motion (ROM) and as
incremental cost per quality-adjusted life year (QALY)
and reported as the average of 5000 probabilistic sensi-
tivity analysis (PSA) simulations. The net monetary
beneﬁt was calculated and employed to estimate the
probability that each programme would be the most
cost-effective at different willingness to pay (WTP) for
one unit increase in the outcome (ROM or QALY).
Additionally, the probability of each strategy was plotted
against the WTP threshold to obtain the cost-
effectiveness acceptability curve. The costs were esti-
mated using a ‘bottom-up’ approach employing Italian
tariffs17 and under the guidance of a panel of experts.
The effectiveness parameters used the results of a recent
clinical trial13 and patient’s level data from a large multi-
centre UK-based clinical trial.18 Since the average
duration of the rehabilitation after TKR is 3 months, we
assumed that each set of devices (ie, two sensors and a
tablet)19 was shared by three patients during the same
year.
Model structure
We employed a previously developed and widely used
Markov model.20 Four different states following the ﬁrst
TKR were considered:
1. Successful TKR,
2. Revision,
3. Successful revision,
4. Death.
Each cycle lasted 1 year; we assumed that each surgery
(ie, both TKRs and revisions) required rehabilitation,
and that TR inﬂuenced neither the probability of having
a second surgery nor the health-related quality of life
(HRQOL) utilities. The perspectives considered in the
model were Ita-NHS and Society. Productivity losses were
estimated assuming that face-to-face rehabilitation lasts
1 h,13 excluding transportation time. The human capital
approach and the average net income in Italy in
20149 10 were used to value the indirect costs. A lifetime
time horizon was employed, correcting the estimates
with the half cycle method and an annual discount rate
of 3% for both costs and outcomes. The surgery, medi-
cation and other procedural costs were not included as
these would not be expected to differ between postsurgi-
cal treatment options.
Transition probabilities
Annual probabilities of death not related to surgery
were estimated from the WHO lifetables,21 while mortal-
ity due to the surgery was based on the UK National
Joint Arthroplasty Registry,22 and was applied to primary
TKR and to revisions. The probability of a ﬁrst revision
is time-dependent and was derived from a parametric
regression-based survival model using data from a large
multicentre UK-based clinical trial.18 According to the
Akaike Information Criterion (AIC) statistics, a γ distri-
bution performed better than the other models tested
and the predictions were estimated on the basis of:
patient’s age, gender and any complications (please see
online supplementary table S1 for further details).
Follow-up in this study was stopped after 9 years and the
probability of a ﬁrst revision beyond this point was based
on extrapolations. Since the survival model could under-
estimate the revision probability after 9 years, different
scenarios were explored. We assumed that the probabil-
ity after 9 years would constantly increase if compared
with the previous cycle employing yearly increment coef-
ﬁcients ranging from 2.5% up to 10%. The re-revision
rate was obtained from the published literature and was
translated into a constant probability.23
Effectiveness of rehabilitation programmes
A recent meta-analysis assessed the clinical effectiveness
of TR in recovering the motor function in different
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populations.15 Agostini et al found that TR after TKR is
clinically more effective than usual care. Among the
studies cited in Agostini et al’s review for TR after
TKR,11–13 two out of three used videoconferencing. The
only study employing sensors for the TR after TKR was a
non-inferiority study,13 using an interactive TR kit. The
set of devices comprised two wireless sensors able to
capture the knee movement and a touch screen
all-in-one computer. The patients undertook half of the
sessions under a physiotherapist’s supervision and the
other half at home. However, the patients enrolled in
the trial did not experience any complications.
Therefore, to avoid unrealistic matches between patients
and clinical outcomes, the following considerations in
assigning the outcome rewards were required. The SR
arm was supposed to receive exclusive face-to-face
rehabilitation, so the clinical outcome of the control
group was applied to the patients in the SR arm. The
SR-TR arm was further divided into two groups: patients
with or without complications. Patients who experienced
any complications received only face-to-face rehabilita-
tion sessions; therefore, the control group outcome was
assigned to them. On the other hand, the remaining
patients in the SR-TR programme did not have any com-
plication and received half of the sessions remotely; con-
sequently, the outcome of the experimental group (ie,
TR) was associated with the patients without complica-
tions. After clinical expert consultation,24 the selected
clinical effectiveness outcome employed in our model
was the knee ﬂexion ROM after 3 months of follow-up.
Health-related quality of life
No studies were identiﬁed which reported exhaustive
results for the HRQOL utilities of patients following a
TR programme after TKR. Therefore, we employed the
data from a large multicentre UK-based clinical trial
(KAT trial)18 to estimate the HRQOL for SR and to
predict SR-TR utilities. This was based on the EuroQol
ﬁve dimensions (EQ-5D) questionnaire, a ﬁve dimen-
sions (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression) and three levels (no
problems, some problems or severe problems) instru-
ment.25 The responses were translated into a numeric
scale using UK weights26 ranging from 1 (full health) to
−0.6 (health states worse than death), and 0 is equiva-
lent to death. The HRQOL utilities were calculated
before and 1 year after any surgery. Since the available
studies for TR after TKR suggested SR-TR to be at least
not inferior to usual care,14 15 we assumed SR-TR to not
inﬂuence HRQOL. However, to further explore the
impact of our assumption, we performed a two-way sensi-
tivity analysis to consider different scenarios—please see
the ‘Sensitivity analyses’ section for further details.
Ordinary least squares and Tobit models were used to
estimate the utilities using the following explanatory vari-
ables: patient’s age, gender, any complication and type
of surgery (ie, ﬁrst TKR or revision; please see online
supplementary table S2 for further details). The
HRQOL decrement was not assessed as we assumed util-
ities would not be inﬂuenced by TR, and it would have
the same impact on both arms of the model.
Costs
On the basis of the model assumptions and the perspec-
tives adopted, direct and indirect cost units are sum-
marised in table 1. Direct costs were limited to the
Italian tariffs for the ambulatory rehabilitation (year
2013)17 and the ambulance transportation (year 2008)27
for the SR programme. The SR-TR programme relied
on the Italian tariffs for rehabilitation and transportation
for the 10 face-to-face sessions, while the cost related to
the 10 telesessions was based on opinions from a panel
of experts in the clinical and Telco areas. Finally, the
costs were inﬂated to 2008 and 2013 euros.28 The cost of
TR was broken down into: hardware, server, internet
and telesessions cost. Since there is no comprehensive
information on cost of TR after TKR, data were obtained
from expert opinions. Hardware cost was elicited from
the engineers of the REal-TIme System laboratory
(ReTIS—Sant’Anna School of Advanced Studies) and
the lifetime of the devices was estimated to be 3 years.
Likewise, the expert advisory group from an Italian
Telco provided costs for the server and for the internet
connection. According to directors of the rehabilitation
units across ‘Area Vasta Nord-Ovest’ in Tuscany, teleses-
sions cost was estimated assuming the medical personnel
cost to be halved.24 Productivity lost was measured con-
sidering the average duration of a face-to-face rehabilita-
tion session.13 Monetisation of indirect cost was
performed using the human capital approach and was
limited to patients younger than 70 years (maximum
pensionable age in Italy).
Sensitivity analysis
To reﬂect the uncertainty in parameters, each PSA simu-
lation uses randomly selected values for the transition
probabilities, the costs, the clinical outcome, the utilities
and the number of rehabilitation sessions. For those
parameters without any information available on the
variation of the mean, the PSA assumed an SE equal to
40% of the mean.30 The probabilistic values for costs
and transition probabilities were obtained using γ and β
probability distributions, respectively, while both the clin-
ical outcome and the number of rehabilitation sessions
used normal distributions. The Cholesky decomposition
method was used to represent uncertainty in the regres-
sion models for HRQOL and prostheses survival
analysis.
One-way sensitivity analysis was employed to estimate
the variation of the cost-effectiveness results according
to the changes in assumptions and single parameters.
Furthermore, a two-way sensitivity analysis was performed
to calculate the incremental cost-effectiveness ratio
(ICER), the cost-effectiveness probability and the prob-
ability of being more effective and less costly varying
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HRQOL assumptions and the number of ambulance
transportation.
This economic evaluation was developed following the
Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) guidelines.31
All the analyses were performed with Excel V.2013
(Microsoft Corporation, USA) and with STATA V.12
(StataCorp LP, USA).
RESULTS
To assess the lifetime costs and effectiveness of SR-TR
and SR, we employed a cohort of 1000 patients with the
KAT trial sample features (44% males, 19% experienced
complications during or after the surgery). However, an
average age of 60 years rather than 70 years was used to
consider the reduction in the average age of the TKR
patients in the next years.5 Additionally, the number of
ambulance transportations was assumed to be 25% of the
number of face-to-face rehabilitation sessions (eg, ﬁve
round trips over 20 sessions for SR and three round trips
over 10 face-to-face sessions for SR-TR). Table 2 reports
the lifetime HRQOL, clinical outcome and cost results
according to the payer perspectives and the percentage
of the ambulance transportations reimbursed out of the
number of face-to-face sessions. When compared with SR,
the incremental cost per ROM gained for SR-TR ranges
from −€117 (Ita-NHS perspective) to −€152 (Society per-
spective; table 3). Figures 1 and 2 present the PSA results
for both perspectives plotted along the cost-effectiveness
plane. Employing the base-case cohort, most of the simu-
lations were located below a €50/ROM threshold, leading
to a 98% probability for SR-TR of being cost-effective.
Likewise, the joint probability for TR being less expensive
and more clinically effective against SR was 86% for the
base case. Since the number of reimbursed ambulance
round trips varies across the different primary care units
(PCU), ﬁgures 3 and 4 show the cost-effectiveness accept-
ability curves reducing the provided number of ambu-
lance transportations from all to none of the face-to-face
rehabilitation sessions. Results were not affected by the
number of ambulance round trips: the probability of
being cost-effectiveness ranged from 83% (no ambulance
transportation) to 100% (all rehabilitation sessions) at
a threshold of €50/ROM. The QALYs gained for the base-
case cohort in the SR arm were 13.02; assuming
Table 1 Parameter values employed in the Markov model
Parameters Value (SE) Source
Probabilities
Death due to any surgery 0.002 22
Death from causes other than surgery Age-adjusted UK population norm 21
First revision Variable–dependent on age, gender
and complication related to TKR
surgery
(ref. 18, supplementary
material)
Re-revision: 0.027 23
Unit costs
Rehabilitation session €43.32 (17.33)* 17
Telerehabilitation session €16.5 (6.6)* 24
Ambulance transportation per round trip €37.60 (15.04)* 27
Hardware (3 years lifetime)
2 sensors €100 Personal communication
Tablet €160 Personal communication
Telco service
Server fee una tantum €137 Personal communication
Server fee per year €2.514 Personal communication
Internet cost (4 months) per patient €40 29
Indirect cost
Productivity lost 1 h/rehabilitation session 13
Average net income €9.75/h 9 10
Clinical outcomes
Standard rehabilitation knee ROM difference after
3 months from follow-up
15.63° (1.18) 13
Standard rehabilitation plus telerehabilitation knee
ROM difference after 3 months from follow-up
18.16° (1.09) 13
HRQOL outcomes
HRQOL utilities for SR Variable–dependent on age, gender,
type of surgery and complication
related to the surgery
(ref. 18,
supplementary material)
*SE was assumed to be equal to 40% of the average.
HRQOL, health-related quality of life; ROM, range of motion; SR, standard rehabilitation; TKR, total knee replacement.
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Table 2 Base-case discounted lifetime: costs, clinical outcome and QALYs according to transportation scenarios and payer
perspectives
Italian NHS Society
SR Telerehabilitation SR Telerehabilitation
Costs
No transportation €904 €840 €1095 €955
25% of the SR sessions €1124 €862 €1315 €977
50% €1326 €874 €1516 €989
75% €1534 €891 €1724 €1005
100% €1769 €923 €1960 €1037
Knee flexion ROM 17.47 19.70 17.47 19.70
QALYs 13.02 – 13.02 –
NHS, National Health Service; QALY, quality-adjusted life year; ROM, range of motion; SR, standard rehabilitation.
Table 3 Base-case and one-way sensitivity analyses
NHS Society
ICERs
Probability
SR-TR is
cost-effective*
Probability SR-TR
is more effective
and less
expensive ICERs
Probability
SR-TR is
cost-effective*
Probability SR-TR
is more effective
and less
expensive
Base case −€117 0.98 0.87 −€152 0.99 0.91
Ambulance transportations
No
transportation
−€29 0.83 0.56 −€63 0.92 0.72
25% of the SR
sessions
−€199 0.99 0.93 −€233 1.00 0.94
75% −€285 1.00 0.94 −€319 1.00 0.94
100% −€375 1.00 0.94 −€408 1.00 0.94
Patients with any complication
35% −€70 0.91 0.71 −€104 0.95 0.81
50% −€74 0.91 0.73 −€107 0.95 0.82
65% −€87 0.91 0.75 −€121 0.95 0.83
80% −€122 0.92 0.79 −€156 0.95 0.84
Telco fee per patient
€30 −€98 0.96 0.83 −€130 0.98 0.89
€50 −€94 0.95 0.81 −€128 0.98 0.87
€80 −€83 0.93 0.77 −€117 0.96 0.85
€100 −€77 0.90 0.74 −€111 0.95 0.82
Sensors cost
€200 −€101 0.97 0.84 −€135 0.99 0.89
€300 −€91 0.95 0.80 −€125 0.98 0.87
€400 −€77 0.93 0.76 −€111 0.97 0.85
€500 −€65 0.90 0.70 −€99 0.95 0.81
Age
40 −€121 0.98 0.87 −€155 0.99 0.91
50 −€117 0.98 0.88 −€151 0.99 0.91
70 −€112 0.97 0.86 −€112 0.97 0.86
80 −€107 0.97 0.87 −€107 0.97 0.87
90 −€108 0.97 0.85 −€108 0.97 0.85
Yearly increment in revision probability after 9 years
2.5% −€113 0.98 0.88 −€147 0.99 0.91
5% −€117 0.98 0.88 −€151 0.99 0.92
7.5% −€114 0.98 0.87 −€148 0.99 0.91
10% −€117 0.98 0.87 −€151 0.99 0.91
Shown are the ICERs, the probability for SR-TR being cost-effective and the probability for SR-TR being more effective and less expensive.
*WTP at €50 per ROM.
ICER, incremental cost-effectiveness ratio; NHS, National Health Service; ROM, range of motion; SR, standard rehabilitation; TR,
telerehabilitation; WTP, willingness to pay.
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the HRQOL experienced by the patients involved in the
SR-TR programme to be equivalent to those involved in
SR, the average lifetime saving was €338 per patient.
Table 4 reports in full detail the cost-utility analysis
results.
Sensitivity analyses
Table 3 reports one-way sensitivity analyses results.
Employing the reference cohort and increasing the
number of patients experiencing complications, the
ICERs decrease up to a saving of €122 per ROM.
Running the model increasing the value for the sensors
cost, for the average age at operation or applying any
Telco fee per patient for the service, reduced the prob-
ability for SR-TR of being cost-effective. Nevertheless,
table 3 showed that the lowest probability of being cost-
effective is 83% (no transportation), while the lowest
value for the joint probability for SR-TR of being less
expensive and more effective is 56% (no transportation).
Table 4 shows the results for the two-way sensitivity ana-
lysis, matching the changes in HRQOL utilities to the per-
centage of the ambulance transportations reimbursed
out of the number of face-to-face sessions. Although TR
is clearly cost-effective if SR-TR is not inferior to SR and
the maximum WTP is €30 000/QALY, the lowest ceiling
ratio necessary to ensure 100% of cost-effectiveness prob-
ability is largely lower. In this sense, if the utilities of the
patients treated with TR were increased by 2.5%, the
ceiling ratio ranges from €600/QALY (10 transportation)
to €3000/QALY (no transportation).
DISCUSSION
This study explored the cost-effectiveness and cost-utility
of TR compared with standard care following TKR. We
used a decision model to assess and forecast the lifetime
costs, clinical and HRQOL effects of a mixed SR and TR
programme against usual care. The results of the base-
case analysis suggested SR-TR is highly cost-effective
Figure 1 Results of probabilistic
sensitivity analysis for the base
case, adopting the Italian NHS
perspective. NHS, National
Health Service; ROM, range of
motion.
Figure 2 Results of probabilistic
sensitivity analysis for the base
case, adopting the Society
perspective. ROM, range of
motion.
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independently from the perspective adopted. Since the
number of the reimbursed ambulance transports
changes across the PCUs, both results for
cost-effectiveness and cost-utility analysis were reported
considering all the possible scenarios (ie, ambulance
transportation between none and all face-to-face
rehabilitation sessions). Reducing the number of trans-
portations decreased the cost-effectiveness probability;
however, even if transportation costs were excluded,
SR-TR was still a cost-effective alternative to usual care.
One-way sensitivity analyses showed that the results of
the model were robust to variations in each parameter.
The cost of sensors was the parameter with the greatest
impact on cost-effectiveness after the number of ambu-
lance transportations provided. Increasing the cost of
the sensors increased the ICER from −€117/ROM for
the base case (ie, sensors cost: €100) to −€64/ROM (ie,
sensors cost: €500), leading to a reduction in the cost-
effectiveness probability from 98% to 90%. Cost-utility
analysis was performed using the utilities belonging to
patients accessing the SR protocol18 and the base-case
scenario assumed no changes in HRQOL for SR-TR
patients. If TR is at least non-inferior to SR, the current
analysis suggests that SR-TR would be highly cost-
effective. Nonetheless, the recently released Italian
guidelines for telemedicine declared that the assessed
programmes would be implemented if the effectiveness
is equal or superior to usual care and the cost is equal
or lower.32 Out of the parameters involved in the sensi-
tivity analyses, we considered paying a fee ranging from
€30 to €100 to the potential service provider. Even in
the worst-case scenario, the probability of SR-TR being
less costly and more effective is high (probability: 74%).
The current analysis showed that TR is clinically more
effective and less expensive for all the considered scen-
arios, but if the transportation is not reimbursed by the
PCU, choosing between SR-TR and SR would be almost
indifferent (ie, probability of being more effective and
less costly: 56%). The authors of the clinical trials asses-
sing TR after TKR justiﬁed remote rehabilitation being
Figure 3 Cost-effectiveness
acceptability curves for the
base-case economic analysis
according to the number of
reimbursed transportations and
adopting the Italian NHS
perspective. NHS, National
Health Service; SR, standard
rehabilitation.
Figure 4 Cost-effectiveness
acceptability curves for base-case
economic analysis according to
the number of reimbursed
transportations and employing the
Society perspective. NHS,
National Health Service; SR,
standard rehabilitation.
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more effective than usual care due to the increased
intensity of the treatment.11–15 Our results showed that
TR could curb spending on healthcare mainly because
of reduced transportation costs. This could restrict the
adoption of SR-TR to those PCUs providing transporta-
tion for rehabilitation after TKR and requiring further
investigation on the WTP for those PCUs not providing
ambulance service.
Whereas a cost-analysis for TR after TKR was published
recently,16 no exhaustive cost-effectiveness or cost-utility
analyses have been undertaken at the time of our evalu-
ation. Tousignant and colleagues documented the costs
for in-home TR after total knee arthroplasty based on a
previous clinical trial. The main ﬁnding of the analysis
was that the cost for the TR arm was signiﬁcantly less than
for the control group.16 TR on average led to save $C263,
95% CI −$C382 to −$C143 (ie, €186, 95% CI −€270 to −
€101), reducing the expenditure by 18%. Not surpris-
ingly, the most important item of cost was the travelling
expenditure, which accounted for 49% of the total cost.
However, the transportation cost reduction for the TR
arm was signiﬁcant if the distance between the healthcare
centre and the patient’s house was >30 km. Our results—
a saving of €230 per patient—agree with Tousignant and
collegues’ estimates; however, some elements should be
taken into account. Beyond the differences due to cross-
country comparison, Tousignant and colleagues’ esti-
mates employed a different treatment scheme, technical
equipment and time horizon. Our cost-effectiveness ana-
lysis considered outpatient physiotherapy—the patients’
travel to the PCUs by ambulance—while Tousignant and
colleagues considered home visits—the physiotherapists’
travel from the healthcare units to patients’ homes.
Second, the equipment used in Tousignant and collea-
gues’ paper was a videoconferencing system (equipment
cost: €12 960), while the current work relies on a kit
composed of two sensors and one tablet (equipment
cost: €260). Finally, our study adopted a lifetime horizon,
while Tousignant and collegues focused on the ﬁrst
4 months after discharge only.
There are a number of limitations associated with this
study. Decision modelling involves assumptions and sim-
pliﬁcations, and cannot perfectly reﬂect actual clinical
practice. The dispersion parameters for some items
involved in our analysis (eg, rehabilitation tariffs, trans-
portation costs) were not available, reducing the accur-
acy of our analysis. However, if any information was not
available on variance of the employed parameters, we
applied a coefﬁcient of variation of 40%,30 which in
some cases could be an overestimate of the uncertainty.
Another limitation that should be taken into account is
the potential selection bias for the trial providing the
clinical outcome.13 Piqueras and colleagues excluded
the patients who experienced any complication.
Therefore, the validity of our results was preserved,
assigning the TR outcome exclusively to the patients
with a positive prognosis. This led to assigning the SR
outcome reward to patients with complications, perhaps
leading to an overestimate of their ROM. Furthermore,
the study focused on a speciﬁc provision and operation
of the outpatient physiotherapy service that might limit
the generalisability of our results. First, the only mode of
transport considered was the ambulance, while in a real
setting private cars and minibuses could also be used.
Moreover, the transportation tariff was assumed to be
the lowest possible one and the travelling time was not
considered in the productivity loss, thereby underesti-
mating these costs. Second, the study assessed only
physiotherapy delivered in hospitals because of the lack
of clinical data for other rehabilitation pathways for TR.
In addition, physiotherapists in a hospital gym setting
usually monitor and instruct many patients
Table 4 Two-way sensitivity analysis according to the SR-TR effect on HRQOL, number of transportations reimbursed and
payer perspective
TR effect on HRQOL
−5% −2.50% +2.50% +5%
ICER (probability cost-effective)* [probability less expensive, more effective]
Italian NHS
No transportation €118(0)[0] €232(0)[0] −€218(1)[0.59] −€118(1)[0.60]
25% of the SR sessions €486(0)[0] €972(0)[0] −€960(1)[0.92] −€485(1)[0.92]
50% €853(0)[0] €1681(0)[0] −€1702(1)[0.99] −€852(1)[0.99]
75% €1229(0)[0] €2460(0)[0] −€2430(1)[1] −€1229(1)[1]
100% €1599(0)[0] €3173(0)[0] −€3140(1)[1] −€1592(1)[1]
Society
No transportation €261(0)[0] €518(0)[0] −504(1)[0.77] −260(1)[0.77]
25% of the SR sessions €629(0)[0] €1258(0)[0] −1245(1)[0.96] −627(1)[0.96]
50% €996(0)[0] €1964(0)[0] −1987(1)[0.99] −995(1)[0.99]
75% €1372(0)[0] €2747(0)[0] −2714(1)[1] −1372(1)[1]
100% €1742(0)[0] €3457(0)[0] −3425(1)[1] −1736(1)[1]
*WTP: €30 000/QALY.
ICER, incremental cost-effectiveness ratio; HRQOL, health-related quality of life; NHS, National Health Service; QALY, quality-adjusted life
year; SR, standard rehabilitation; TR telerehabilitation; WTP, willingness to pay.
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simultaneously; this could also be possible employing
TR, but perhaps it would be more time consuming,
thereby leading to higher medical personnel costs. Even
though assumptions are necessary for decision model-
ling, some of them could not reﬂect reality; this raises
questions that should be addressed in future research
developing ad hoc studies.
Given the innovativeness of the treatment, Italian tele-
medicine guidelines32 stated that tariffs for telemedicine
should be comparable to those for the available usual
care services. However, TR could lead to an increase in
the efﬁciency of delivering treatment by reducing the
effort of the physiotherapist. These performance issues
should be taken into account in the tariffs deﬁnition.
Likewise, Agostini et al15 found a signiﬁcant positive
effect for TR against SR; however, further clinical long-
term effectiveness evidences are required to conﬁrm the
results. In this sense, HRQOL and prosthesis survival
studies for TR after TKR ought to be developed to
improve the robustness of our estimates.
Our paper has important implications for the health-
care services since the number of TKR performed across
Europe has increased dramatically in the past decade.
The growth rate varies across the European countries; for
instance, if France faced an increment in the TKR per-
formed between 2000 and 2012 by 80%, in Denmark the
number of knee prostheses implanted has more than
tripled in the same period.33 The metrics for Italy and the
UK appear comparable to this picture, with the number
of TKR increasing from 27 959 to 63 048 (2001–2012)3
and from 13 517 to 82 267 (2003–2013), respectively.22
These statistics probably reﬂect the number of knee
rehabilitations performed across Europe, suggesting that
physiotherapy after TKR has an impact on the health-
care budgets. Evidence showed telerehabilitation could
be a cost-effective programme, and less costly and more
effective if transportation is provided by PCUs. Likewise,
considering productivity lost would reinforce our results,
justifying TR adoption. Another interesting point is that
the increased efﬁciency could reduce the time necessary
to treat patients accessing the TR programme. If this
reduction will be demonstrated, TR could allow the
reallocation of resources to other disease areas or to
patients with a worse prognosis. Despite the difﬁculties
in telemedicine diffusion in Italy, in the past 5 years
there was an increasing interest from the Italian Ministry
of Health for telecare.34 This led to deﬁne the telemedi-
cine guidelines, practically setting the basis for redesign-
ing the Ita-NHS and integrate e-health programmes
within it.32 Even though further research is needed to
validate our results, TR after TKR has been shown to be
able to curb spending in healthcare and to improve clin-
ical outcomes in the short term.
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